• Outlook Therapeutics published an on-demand video webcast of CEO Bob Jahr’s Virtual Investor “Why Now” conference segment: here.
• Presentation highlighted FDA approval of LYTENAVA on July 24, 2026 as the only FDA-approved ophthalmic bevacizumab for wet AMD.
• Jahr outlined a shift to commercial-stage operations, citing launch preparations in the U.S. alongside an existing commercial presence in Europe.
• Remarks focused on targeting an established market where bevacizumab is widely used off label, positioning LYTENAVA as a potential standard-of-care change.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270901PRIMZONEFULLFEED9816828) on August 27, 2026, and is solely responsible for the information contained therein.